Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18927301 | PHARMACEUTICAL COMPOSITIONS COMPRISING COLLAGENASE I and COLLAGENASE II | October 2024 | December 2024 | Allow | 2 | 0 | 0 | No | No |
| 18909225 | METHODS OF TREATING OR PREVENTING A CARDIOVASCULAR SYSTEM COMPLICATION OF SICKLE CELL DISEASE WITH AN ANTI-G-CSFR ANTIBODY | October 2024 | April 2025 | Allow | 7 | 1 | 1 | No | No |
| 18830877 | ANTI IL-6 DOMAIN ANTIBODIES WITH FATTY ACID SUBSTITUENTS | September 2024 | April 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18817109 | ANTI-IL-18BP ANTIBODIES | August 2024 | April 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 18773461 | ANTI-TRANSFERRIN RECEPTOR ANTIBODY-PMO CONJUGATES FOR INDUCING DMD EXON 44 SKIPPING | July 2024 | March 2025 | Allow | 8 | 1 | 1 | No | No |
| 18615520 | NUCLEIC ACID MOLECULES ENCODING CLOSTRIDIUM HISTOLYTICUM COLLAGENASE I AND METHODS OF PRODUCING THE SAME | March 2024 | June 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18441998 | METHODS OF TREATMENT OR PREVENTION OF IMMUNE RESPONSES AND INFLAMMATORY DISEASES WITH ANTAGONISTIC CD40 MONOCLONAL ANTIBODIES | February 2024 | May 2025 | Allow | 15 | 1 | 1 | No | No |
| 18413753 | AMELIORATION AND TREATMENT OF INFARCTION DAMAGE WITH A POLYPEPTIDE SEGEMENT OF BNIP3 | January 2024 | February 2025 | Allow | 13 | 2 | 1 | Yes | No |
| 18390569 | METHODS FOR INDUCING AN IMMUNE RESPONSE BY ADMINISTERING ACTIVATED MESENCHYMAL STEM CELLS | December 2023 | April 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18505590 | METHOD OF ASSESSING REGULATION OF AN IMMUNE RESPONSE TO AN ADMINISTERED AGENT BY MEASURING ACTIVATION OF NODOSE GANGLION NEURONS | November 2023 | May 2025 | Allow | 19 | 3 | 1 | No | No |
| 18459465 | PROPERDIN BINDING PROTEIN AND USE THEREOF | September 2023 | August 2024 | Allow | 11 | 2 | 1 | Yes | No |
| 18453691 | Antagonistic CD40 Monoclonal Antibodies and Uses Thereof | August 2023 | May 2025 | Allow | 20 | 1 | 1 | Yes | No |
| 18357639 | METHOD OF TREATING DIABETES WITH FGF21 AND GLP1 DOUBLE GENE-MODIFIED CELL | July 2023 | June 2025 | Allow | 22 | 2 | 1 | No | No |
| 18346205 | HETERODIMERIC RELAXIN FUSIONS AND USES THEREOF | July 2023 | August 2024 | Allow | 14 | 0 | 0 | No | No |
| 18329308 | NUCLEIC ACIDS ENCODING CLOSTRIDIUM HISTOLYTICUM DELTA TOXIN AND METHODS OF PRODUCING THE SAME | June 2023 | May 2025 | Abandon | 23 | 2 | 0 | No | No |
| 18140121 | METHODS OF TREATING IRON OVERLOAD WITH A BMP INHIBITOR | April 2023 | June 2025 | Allow | 26 | 1 | 1 | No | No |
| 18301924 | Anti-CD30 and Anti-CD3 Bispecific Antibodies and Methods of Immunotherapy for CD30+ Malignancies | April 2023 | April 2025 | Allow | 24 | 1 | 1 | No | No |
| 18193581 | NATRIURETIC PEPTIDE RECEPTOR 1 ANTIBODIES AND METHODS OF USE | March 2023 | April 2025 | Allow | 25 | 0 | 1 | Yes | No |
| 18193393 | TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRBeta ANTIBODY | March 2023 | November 2024 | Abandon | 20 | 0 | 1 | No | No |
| 18125353 | APLNR Modulators and Uses Thereof | March 2023 | December 2024 | Abandon | 21 | 0 | 1 | No | No |
| 18163667 | ANTI-CD30 ANTIBODIES | February 2023 | February 2025 | Allow | 25 | 1 | 1 | Yes | No |
| 18156617 | ANTIBODY ENDOHEDRAL METALLOFULLERENE CONJUGATE AND USES THEREOF | January 2023 | June 2025 | Abandon | 29 | 4 | 1 | Yes | No |
| 17946916 | NUCLEIC ACIDS ENCODING SWITCH RECEPTORS USING IL-9 RECEPTOR SIGNALING DOMAINS | September 2022 | September 2024 | Allow | 24 | 2 | 1 | No | No |
| 17933055 | METHODS OF TREATMENT OF ARTHRITIS AND/OR PSORIASIS WITH PHARMACEUTICAL FORMULATIONS OF ETANERCEPT | September 2022 | September 2024 | Allow | 24 | 1 | 1 | No | No |
| 17881413 | KIT FOR PREPARING DISEASE-TREATING AGENT, DISEASE-TREATING AGENT AND METHOD FOR PREPARING DISEASE-TREATING AGENT | August 2022 | December 2024 | Abandon | 28 | 1 | 1 | No | No |
| 17814221 | Method of Making Anti-Pro/Latent Myostatin Antibodies | July 2022 | December 2024 | Allow | 29 | 2 | 1 | No | No |
| 17859130 | METHOD OF USING NAP-2 AND TGF-alpha TO IMPROVE CARDIAC FUNCTION | July 2022 | March 2025 | Allow | 32 | 1 | 0 | Yes | No |
| 17810423 | C-KIT ANTIBODIES AND METHOD FOR TREATING CANCER WITH SUCH | July 2022 | August 2024 | Allow | 25 | 1 | 1 | No | No |
| 17838863 | T-CELL REACTIVITY PLATFORM | June 2022 | November 2024 | Abandon | 29 | 1 | 1 | No | No |
| 17837943 | GRP78-BINDING ANTIBODIES AND USES THEREOF IN DETECTING OR NEUTRALIZING GRP78 | June 2022 | August 2024 | Allow | 26 | 1 | 1 | No | No |
| 17836473 | NUCLEIC ACIDS ENCODING CX3CR1-BINDING POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS | June 2022 | September 2024 | Allow | 28 | 1 | 1 | No | No |
| 17827100 | Inhibition of Vascular Matrix Metalloproteinase-9 to Treat Ischemic Injury | May 2022 | February 2025 | Abandon | 32 | 1 | 1 | No | No |
| 17725142 | ANTI-CD39 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-CD39 ANTIBODIES AND METHODS OF USING ANTI-CD39 ANTIBODIES | April 2022 | October 2024 | Abandon | 30 | 1 | 1 | No | No |
| 17718087 | IL-12 HETERODIMERIC FC-FUSION PROTEINS | April 2022 | August 2024 | Allow | 28 | 2 | 1 | No | No |
| 17703747 | ANTI-BAG3 ANTIBODIES AS THERAPEUTIC REAGENT IN CARDIOVASCULAR DISEASE | March 2022 | November 2024 | Allow | 32 | 2 | 1 | Yes | No |
| 17694295 | USE OF SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR LEVELS TO INDICATE PREVENTION OF CARDIOVASCULAR DISEASE WITH A STATIN | March 2022 | May 2025 | Allow | 38 | 2 | 0 | No | No |
| 17579355 | METHODS OF DIAGNOSING, DETERMINING THE PROGRESSION OF, AND TREATING A PROSTATE CANCER | January 2022 | September 2024 | Allow | 32 | 2 | 1 | No | No |
| 17626755 | ANTI-8-HYDROXY-2'-DEOXYGUANOSINE ANTIBODY OR ANTIBODY FRAGMENT THEREOF, PRODUCTION METHOD, KIT, MEASURING METHOD, AND DEVICE FOR MEASUREMENT | January 2022 | March 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17486820 | HUMAN APOB100 EPITOPES, METHODS AND USES FOR MODULATING INFLAMMATORY RESPONSES, AND TREATING ADVERSE CARDIOVASCULAR EVENTS, DISEASE AND ATHEROSCLEROSIS | September 2021 | June 2025 | Allow | 45 | 3 | 1 | Yes | No |
| 17448389 | METHODS FOR TREATING METABOLIC DISEASES BY INHIBITING MYOSTATIN ACTIVATION | September 2021 | May 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17405124 | METHODS OF USING FLT3L-Fc FUSION PROTEINS FOR THE TREATMENT OF DISEASES | August 2021 | December 2024 | Abandon | 40 | 2 | 2 | No | No |
| 17359211 | TREATMENT OF CANCER USING HUMANIZED ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR | June 2021 | September 2024 | Allow | 39 | 2 | 1 | No | No |
| 17239983 | METHOD FOR TREATING FIBROSIS WITH AN ANTI-GDF-15 ANTIBODY | April 2021 | March 2025 | Allow | 47 | 4 | 1 | No | No |
| 17202790 | Methods of Treatment with Anti-PACAP Antibodies | March 2021 | August 2024 | Allow | 41 | 2 | 1 | No | Yes |
| 17271767 | METHOD TO ASSESS CAR FUNCTIONALITY | February 2021 | December 2024 | Abandon | 46 | 0 | 1 | No | No |
| 17150457 | METHODS OF ADMINISTERING MESENCHYMAL STEM CELLS ACTIVATED BY CYTOKINES FOR ENHANCING IMMUNOSUPPRESSION | January 2021 | August 2024 | Allow | 43 | 2 | 1 | No | No |
| 17256553 | ANTI-CD6 ANTIBODY-GROWTH FACTOR COMPLEX FOR TREATING AUTOIMMUNE DISEASES | December 2020 | March 2025 | Allow | 50 | 2 | 1 | No | No |
| 17250259 | POZIOTINIB COMBINATIONS WITH AN ANTI-HER1, HER2 OR HER4 ANTIBODY AND METHODS OF USE THEREOF | December 2020 | January 2025 | Abandon | 49 | 1 | 1 | No | No |
| 17077433 | METHOD FOR TREATING PULMONARY HYPERTENSION WITH ANTIBODIES TO HUMAN RESISTIN | October 2020 | October 2024 | Allow | 48 | 3 | 1 | Yes | No |
| 16979471 | NUCLEIC ACIDS ENCODING IL-13 RECEPTOR ALPHA 2 (IL13RA2) CHIMERIC ANTIGEN RECEPTOR FOR TUMOR SPECIFIC T CELL IMMUNOTHERAPY | September 2020 | July 2024 | Allow | 46 | 1 | 1 | Yes | No |
| 16987237 | ANTI-ASGR-1 MONOCLONAL INHIBITORY ANTIBODIES | August 2020 | March 2024 | Allow | 43 | 4 | 1 | No | No |
| 16964785 | METHODS FOR PREVENTING ISCHEMIA REPERFUSION INJURY IN AN ORGAN WITH ANTIBODY ANTAGONISTS OF IL-33 | July 2020 | July 2024 | Allow | 48 | 6 | 1 | No | No |
| 16772260 | Cell Comprising a Chimeric Antigen Receptor or a Transgenic T-Cell Receptor and Comprising a Chimeric TNF Receptor | June 2020 | February 2025 | Allow | 56 | 3 | 1 | Yes | No |
| 16753216 | TRANSTHYRETIN IMMUNOGLOBULIN FUSIONS | April 2020 | December 2024 | Allow | 56 | 5 | 1 | Yes | No |
| 16711067 | TIE2 RECEPTOR ACTIVATION FOR GLAUCOMA | December 2019 | January 2024 | Abandon | 50 | 4 | 1 | No | Yes |
| 16677267 | T-CELLS EXPRESSING ANTI-LIV1 CHIMERIC ANTIGEN RECEPTOR | November 2019 | January 2025 | Allow | 60 | 5 | 1 | No | No |
| 16461258 | METHOD FOR INCREASING THE SECRETION LEVELS OF INTERLEUKIN 2 AND MUTEINS THEREOF BY INTRODUCING A POINT MUTATION | May 2019 | March 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16248507 | ANTI-APOC3 ANTIBODIES AND COMPOSITIONS THEREOF | January 2019 | November 2019 | Allow | 10 | 2 | 1 | Yes | No |
| 16315684 | TREATMENT OF ISCHEMIA REPERFUSION INJURY USING ALPHA-2 MACROGLOBULIN | January 2019 | March 2020 | Allow | 14 | 2 | 1 | Yes | No |
| 16056068 | ANGIOPOIETIN-LIKE PROTEIN 8 POLYPEPTIDE FRAGMENTS AND COMPOSITIONS THEREOF | August 2018 | March 2020 | Allow | 19 | 2 | 1 | No | No |
| 15992567 | KIT FOR IMMUNOLOGICAL DETECTION OF TNF-ALPHA, STNFR1 AND IL-8 IN PROSTATE CANCER | May 2018 | April 2019 | Allow | 10 | 1 | 0 | Yes | No |
| 15951929 | FOLLISTATIN IN TREATING DUCHENNE MUSCULAR DYSTROPHY | April 2018 | May 2020 | Allow | 25 | 2 | 1 | No | No |
| 15820943 | Methods Of Protecting a Solid Organ Transplant Tissue With Angiopoietin-2 Antibodies | November 2017 | April 2019 | Allow | 17 | 1 | 1 | Yes | No |
| 15800512 | METHODS OF TREATING A SUBJECT HAVING HEART FAILURE THAT INCLUDE DETECTING LEVELS OF GALECTIN-3 AND SOLUBLE ST2 | November 2017 | April 2019 | Allow | 17 | 1 | 1 | No | No |
| 15716005 | Etanercept Formulations Stabilized with Xylitol | September 2017 | October 2018 | Allow | 17 | 1 | 1 | Yes | No |
| 15644450 | METHODS FOR TREATING CENTRAL OR PERIPHERAL NERVOUS SYSTEM DAMAGE | July 2017 | August 2019 | Allow | 26 | 1 | 1 | No | No |
| 15506665 | NEPRILYSIN AS HEART FAILURE PROGNOSTIC MARKER | February 2017 | September 2018 | Allow | 19 | 1 | 1 | No | No |
| 15376358 | TREATMENT OF MYOCARDIAL INFARCTION USING TGF BETA ANTAGONISTS | December 2016 | December 2019 | Allow | 36 | 3 | 1 | Yes | No |
| 15070788 | METHODS OF TREATING HEDGEHOG-RELATED DISEASES WITH AN ANTI-LGR5 ANTIBODY | March 2016 | November 2018 | Allow | 32 | 2 | 1 | No | No |
| 14893122 | Inflammatory Disease Treatment Composition Including Anti-Myosin Regulatory Light-Chain Polypeptide Antibody | November 2015 | June 2017 | Allow | 19 | 2 | 1 | Yes | No |
| 14879702 | ANTI-LRP5 ANTIBODIES AND METHODS OF USE | October 2015 | August 2016 | Allow | 10 | 0 | 1 | No | No |
| 14762373 | FOLLISTATIN IN TREATING DUCHENNE MUSCULAR DYSTROPHY | July 2015 | January 2018 | Allow | 30 | 2 | 1 | No | No |
| 14598664 | Methods of Treating Cancer With Antibodies That Target the Insulin-Like Growth Factor Type I Receptor (IGF-1R) | January 2015 | April 2016 | Allow | 15 | 3 | 1 | Yes | No |
| 14388649 | ANTI-LAMP5 ANTIBODY AND UTILIZATION THEREOF | January 2015 | May 2017 | Allow | 32 | 3 | 1 | Yes | No |
| 14389219 | THROMBIN/PLASMIN-REGULATED ANTIBODIES THAT BIND TFPI | September 2014 | February 2017 | Allow | 28 | 3 | 1 | Yes | No |
| 14386250 | METHOD FOR USE IN THE TREATMENT OF ANEURYSM | September 2014 | October 2016 | Allow | 25 | 3 | 1 | No | No |
| 14446073 | METHODS OF USING AN ANTIBODY TO INHIBIT WNT-MEDIATED SIGNALING IN CANCER | July 2014 | June 2015 | Allow | 11 | 1 | 1 | Yes | No |
| 14306992 | COMBINATION OF AN ANTI-EDB FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART | June 2014 | November 2015 | Allow | 17 | 2 | 1 | Yes | No |
| 14360678 | METHODS OF REGULATING ANGIOGENESIS BY ADMINISTERING AGENTS WHICH INCREASE APOB-100 POLYPEPTIDE | May 2014 | January 2017 | Allow | 31 | 3 | 1 | No | No |
| 14280940 | ALTERATION OF CELL MEMBRANE FOR NEW FUNCTIONS USING IL-2 and STREPTAVIDIN | May 2014 | September 2015 | Allow | 16 | 1 | 1 | Yes | No |
| 14357971 | USE OF FIBROMODULIN AND LUMICAN FOR INCREASING MUSCLE MASS | May 2014 | July 2015 | Allow | 14 | 1 | 1 | No | No |
| 14357393 | USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS FOR TREATING CONTRAST-INDUCED NEPHROPATHY | May 2014 | January 2016 | Allow | 21 | 1 | 1 | No | No |
| 14357204 | METHODS FOR TREATING KIDNEY DISEASE WITH FRAGMENTS OF APOB-100 | May 2014 | October 2015 | Allow | 18 | 2 | 1 | Yes | No |
| 14129446 | LRP1 AS KEY RECEPTOR FOR THE TRANSFER OF STERIFIED CHOLESTEROL FROM VERY-LOW-DENSITY LIPOPROTEINS (VLDL) TO ISCHAEMIC CARDIAC MUSCLE | March 2014 | May 2015 | Allow | 16 | 1 | 1 | No | No |
| 14205170 | METHOD OF SCREENING FOR AN AGENT THAT ENHANCES BEIGE FAT ADIPOGENESIS | March 2014 | April 2016 | Allow | 25 | 1 | 1 | No | No |
| 14152837 | MUTANT PROTEIN CAPABLE OF BINDING SPECIFICALLY AND QUICKLY TO TROPONIN I DERIVED FROM HUMAN MYOCARDIUM | January 2014 | July 2014 | Allow | 6 | 1 | 0 | No | No |
| 14140849 | USE OF EPIDERMAL GROWTH FACTOR FOR THE MORPHOFUNCTIONAL RESTORATION OF PERIPHERAL NERVES IN DIABETIC NEUROPATHY | December 2013 | January 2015 | Allow | 13 | 1 | 0 | Yes | No |
| 14088097 | METHODS FOR TREATING TOURNIQUET-INDUCED INJURIES | November 2013 | December 2014 | Allow | 13 | 1 | 1 | No | No |
| 14116075 | CETP FRAGMENTS | November 2013 | March 2015 | Allow | 16 | 1 | 1 | Yes | No |
| 14000850 | METHODS FOR TREATING LIVER INFLAMMATION IN A SUBJECT SUFFERING FROM NON-ALCOHOLIC STEATOHEPATITIS | October 2013 | March 2016 | Allow | 31 | 2 | 1 | No | No |
| 13953622 | CHIMERIC IMMUNORECEPTOR USEFUL IN TREATING HUMAN CANCERS | July 2013 | August 2015 | Allow | 24 | 2 | 1 | No | No |
| 13636578 | METHODS FOR CARDIOPROTECTION AND CARDIOREGENERATION WITH DIMERS OF EGF FAMILY LIGANDS | April 2013 | January 2015 | Allow | 27 | 1 | 1 | No | No |
| 13827023 | INHIBITION OF MYPB-C BINDING TO MYOSIN AS A TREATMENT FOR HEART FAILURE | March 2013 | January 2015 | Allow | 23 | 2 | 1 | No | Yes |
| 13793931 | THERAPEUTIC APPLICATION OF ADIPONECTIN IN PATIENTS WITH VENTRICULAR FIBRILLATION | March 2013 | June 2014 | Allow | 15 | 0 | 1 | No | No |
| 13713594 | USE OF A PEPTIDE FRAGMENT OF CD44V6 IN THE TREATMENT OF OPHTHALMIC DISEASES | December 2012 | August 2014 | Allow | 20 | 1 | 1 | No | No |
| 13680866 | METHODS FOR IDENTIFYING A GLP-1 SECRETAGOGUE | November 2012 | July 2015 | Allow | 32 | 1 | 1 | Yes | No |
| 13654919 | Etanercept Formulations Stabilized with Xylitol | October 2012 | June 2015 | Abandon | 31 | 4 | 1 | No | No |
| 13552533 | METHODS OF TREATING CARDIOVASCULAR DISEASES AND PREDICTING THE EFFICACY OF EXERCISE THERAPY | July 2012 | January 2014 | Allow | 18 | 1 | 1 | Yes | No |
| 13534833 | METHODS FOR INHIBITING HEMATOPOIESIS WITH A HEDGEHOG ANTAGONIST | June 2012 | November 2013 | Allow | 17 | 1 | 1 | No | No |
| 13530580 | METHODS FOR TREATING REPERFUSION INJURIES USING FLAGELLIN | June 2012 | August 2013 | Allow | 14 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HOWARD, ZACHARY C.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 31.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HOWARD, ZACHARY C works in Art Unit 1674 and has examined 174 patent applications in our dataset. With an allowance rate of 89.7%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 31 months.
Examiner HOWARD, ZACHARY C's allowance rate of 89.7% places them in the 69% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by HOWARD, ZACHARY C receive 2.09 office actions before reaching final disposition. This places the examiner in the 70% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by HOWARD, ZACHARY C is 31 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +13.3% benefit to allowance rate for applications examined by HOWARD, ZACHARY C. This interview benefit is in the 54% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 30.3% of applications are subsequently allowed. This success rate is in the 51% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 61.7% of cases where such amendments are filed. This entry rate is in the 84% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 94.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 56.4% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 20.7% of allowed cases (in the 99% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.8% of allowed cases (in the 75% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.